ConforMIS Stock News

The FDA has given 510(k) clearance for Conformis Inc's (NASDAQ: CFMS) Identity Imprint Knee Replacement System, available in both cruciate-retaining (CR) and posterior stabilized (PS) versions. I

These penny stocks just released big news; will they be on your watchlist? The post Best Penny Stocks to Buy?

Leveraging Conformis' extensive library of personalized knee design data and patient images, Identity Imprint is designed to match patients' anatomy with an optimal arthroplasty solution while at the

Conformis, Inc. (CFMS) CEO Mark Augusti on Q1 2021 Results - Earnings Call Transcript

ConforMIS (CFMS) delivered earnings and revenue surprises of -12.50% and -0.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BILLERICA, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today fin

Creating a penny stock watchlist? You should check these 3 out The post Best Penny Stocks to Buy?

The stock price of ConforMIS Inc (NASDAQ: CFMS) increased by over 10% pre-market. This is why it happened.

BILLERICA, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific instr

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand Commercial Interest in Accurate, Disposable, Patient-Specific Instrumentation Continues to Expand

BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the mark

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and re

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and re

ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).